ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1294

Anti-Inflammatory Effect Of Resveratrol As a Dietary Supplement In An Antigen-Induced Arthritis Rat Model

Romina R. Riveiro-Naveira1, Jesus Loureiro1, Alberto Centeno-Cortés2, Eduardo López-Peláez2, Carlos Vaamonde-García1, M. Noa Valcárcel-Ares1, Francisco J. Blanco3 and Maria J. López-Armada1, 1Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, 2Experimental Surgery Unit, CHU A Coruña, A Coruña, Spain, 3Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Animal models, immune response, Inflammation, resveratrol and synovial cells, synovial fluid

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Animal Models I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Inflammatory cells like macrophages, lymphocytes and neutrophils in hyperplasic synovial tissue have been identified as key players in the onset and development of rheumatoid arthritis (RA). Resveratrol (RSV) is a natural antioxidant with potent immunomodulatory and anti-inflammatory properties. The aim of this study was to investigate the preventive effect of dietary resveratrol and its ability to suppress inflammatory arthritis progression in an acute antigen-induced arthritis (AIA) rat model.

Methods: Six-week-old female Lewis rats were randomized into four study groups: healthy group (n=19), AIA group (n=24), RSV group (n=26) and diclofenac (DCF) group (n=17). RSV (2 mg/day) was administered daily by oral gavage as a dietary supplement beginning one month before AIA induction until sacrifice day, 48h after intraarticular injection. DCF (1,2 mg/day) was orally administered three days before AIA induction until sacrifice day. Joint swelling was assessed by measuring the mediolateral diameter of both right and left knee joints with a digital calliper. Severity of inflammation was evaluated using a blind damage scoring system (H&E). To characterize inflammatory cell infiltration and chemokine levels, CD68, CD3 and MCP-1 expression were evaluated by immunohistochemistry. 

Results: On day 2 after intraarticular injection, RSV animals exhibited significant reduced knee swelling, similar to DCF group, in comparison to AIA animals (mediolateral diameter mean: RSV 7,775 mm ± 0,169, n=26; DCF 7,776 mm ± 0,253, n=17 vs. AIA 8,281 ± 0,127, n=24; p<0,05). Accordingly, histopatological evaluation demonstrated a reduction in synovial hyperplasia and cell infiltration in both RSV and DCF groups compared with AIA animals. CD68 and CD3 infiltrate was significantly attenuated in RSV rats synovium (0,843 ± 0,369, n=5 and 1,290 ± 0,198, n=19, respectively) compared with AIA group (CD68 3,741 ± 1,428, n=5 and CD3 2,868 ± 0,5707, n=18, p<0,05), similar to DCF group (CD68 1,656 ± 0,522, n=13 and CD3 1,753 ± 0,359, n=15). MCP1 levels in the synovium were significantly attenuated in RSV and DCF groups compared with AIA animals (3,167 ± 0,2649 and 2,453 ± 0,628, respectively vs. AIA 4,400 ± 0,4922, p<0,05).

Conclusion: The results of this study suggest that a dietary supplement with the natural antioxidant resveratrol can effectively control inflammation and could exert a protective effect against RA establishment and progression.


Disclosure:

R. R. Riveiro-Naveira,
None;

J. Loureiro,
None;

A. Centeno-Cortés,
None;

E. López-Peláez,
None;

C. Vaamonde-García,
None;

M. N. Valcárcel-Ares,
None;

F. J. Blanco,
None;

M. J. López-Armada,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-inflammatory-effect-of-resveratrol-as-a-dietary-supplement-in-an-antigen-induced-arthritis-rat-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology